Our findings suggest that targeting the NRF2/GPX4 pathway and inducing ferroptosis may be an effective strategy for enhancing chemo-sensitivity in AML patients, and may lead to the development of novel combination therapies. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.